

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

5-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11 11-12 13-14
14-15

exact/norm bonds :

7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15

exact bonds :

5-13 8-13 13-14

normalized bonds :



1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom



chain nodes :

18

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

5-13 14-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11 11-12 13-14
14-15

exact/norm bonds :

7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15 14-18

exact bonds :

5-13 8-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6



isolated ring systems :

containing 1 : 7 :

G1:O,S,N,X,Ak,CN,NO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

5-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11
11-12 13-14 14-15

exact/norm bonds :

7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15

exact bonds :

5-13 8-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom

10/530,101

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|----|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | JUL 20 | Powerful new interactive analysis and visualization software, STN AnaVist, now available |
| NEWS | 4 | AUG 11 | STN AnaVist workshops to be held in North America |
| NEWS | 5 | AUG 30 | CA/CAPLUS - Increased access to 19th century research documents |
| NEWS | 6 | AUG 30 | CASREACT - Enhanced with displayable reaction conditions |
| NEWS | 7 | SEP 09 | ACD predicted properties enhanced in REGISTRY/ZREGISTRY |
| NEWS | 8 | OCT 03 | MATHDI removed from STN |
| NEWS | 9 | OCT 04 | CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added to core patent offices |
| NEWS | 10 | OCT 06 | STN AnaVist workshops to be held in North America |
| NEWS | 11 | OCT 13 | New CAS Information Use Policies Effective October 17, 2005 |
| NEWS | 12 | OCT 17 | STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAPLUS documents for use in third-party analysis and visualization tools |
| NEWS | 13 | OCT 27 | Free KWIC format extended in full-text databases |
| NEWS | 14 | OCT 27 | DIOGENES content streamlined |
| NEWS | 15 | OCT 27 | EPFULL enhanced with additional content |
| NEWS EXPRESS | | | JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005 |
| NEWS HOURS | | | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | | | General Internet Information |
| NEWS LOGIN | | | Welcome Banner and News Items |
| NEWS PHONE | | | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | | | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:09:47 ON 29 OCT 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

10/530,101

FULL ESTIMATED COST

| ENTRY | SESSION |
|-------|---------|
| 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 11:09:58 ON 29 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 OCT 2005 HIGHEST RN 866318-76-5
DICTIONARY FILE UPDATES: 27 OCT 2005 HIGHEST RN 866318-76-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*



Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10530101.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :

10/530,101

5-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11 11-12 13-14
14-15

exact/norm bonds :

7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15

exact bonds :

5-13 8-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 11:10:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 37 TO ITERATE

100.0% PROCESSED 37 ITERATIONS

29 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 376 TO 1104


PROJECTED ANSWERS: 257 TO 903

L2 29 SEA SSS SAM L1

10/530,101

=> d scan


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyridine-2-methanol, 3-[2-(methylthio)-4-pyrimidinyl]-
α-phenyl- (9CI)
MF C19 H16 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):28

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)
MF C28 H29 F N6 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI)
MF C31 H36 F N7 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 2-Pyrimidinamine, 5-bromo-4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-
 a]pyridin-3-yl]-N-cyclopentyl- (9CI)
 MF C22 H18 Br Cl F N5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-
 yl]-N-cyclopentyl- (9CI)
 MF C23 H22 Cl N5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Methanesulfonamide, N-[2-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]ethyl]- (9CI)
 MF C26 H31 N7 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)-N,N-dimethyl- (9CI)
 MF C25 H28 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(dimethylamino)phenyl]- (9CI)
 MF C27 H35 N7

10/530,101




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetic acid, [4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenoxy]-, ethyl ester (9CI)
MF C31 H36 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-methyl- (9CI)
MF C22 H23 F N6



10/530,101


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)
MF C28 H31 F N6




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (9CI)
MF C26 H26 F4 N6




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-(1-pyrrolidinyl)butyl]- (9CI)
MF C26 H26 Cl F3 N6




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI)
 MF C19 H12 F4 N4 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-2-propenyl- (9CI)
 MF C21 H15 F4 N5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 2-Pyrimidinamine, 4-[2-[2-(cyclopentylamino)-4-pyridinyl]pyrazolo[1,5-
 a]pyridin-3-yl]-N-(1-methylethyl)- (9CI)
 MF C24 H27 N7




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(
 cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)
 MF C27 H28 Cl F N6




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Phenol, 4-[5-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-
 pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI)
 MF C27 H30 N6 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
 MF C22 H17 F4 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl- (9CI)
 MF C25 H25 Cl N6



10/530,101


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Phosphoric acid, 4-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl bis(phenylmethyl) ester (9CI)
MF C41 H45 N6 O5 P



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-phenyl- (9CI)
MF C27 H30 N6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-phenoxyphenyl)- (9CI)
MF C33 H34 N6 O

10/530,101




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-
[(dimethylamino)methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)
MF C30 H36 F N7




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(
(methylsulfinyl)-4-pyrimidinyl]- (9CI)
MF C22 H22 F N5 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI)
 MF C25 H29 Br N6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinyl)ethyl]- (9CI)
 MF C25 H23 Cl F4 N6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



CN(C)CCCCNc1ncnc2c1cnc3cc(F)(F)Fcc32C4=CC=C(C(F)(F)F)C=C4

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)- (9CI)
MF C20 H12 F7 N5



ALL ANSWERS HAVE BEEN SCANNED

STN INTERNATIONAL LOGOFF AT 11:10:43 ON 29 OCT 2005



chain nodes :

18

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

5-13 14-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11
11-12 13-14 14-15

exact/norm bonds :

7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15 14-18

exact bonds :

5-13 8-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

G1:O,S,N,X,Ak,CN,NO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS

10/530,101

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|----|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | JUL 20 | Powerful new interactive analysis and visualization software, STN AnaVist, now available |
| NEWS | 4 | AUG 11 | STN AnaVist workshops to be held in North America |
| NEWS | 5 | AUG 30 | CA/CAPLUS -Increased access to 19th century research documents |
| NEWS | 6 | AUG 30 | CASREACT - Enhanced with displayable reaction conditions |
| NEWS | 7 | SEP 09 | ACD predicted properties enhanced in REGISTRY/ZREGISTRY |
| NEWS | 8 | OCT 03 | MATHDI removed from STN |
| NEWS | 9 | OCT 04 | CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added to core patent offices |
| NEWS | 10 | OCT 06 | STN AnaVist workshops to be held in North America |
| NEWS | 11 | OCT 13 | New CAS Information Use Policies Effective October 17, 2005 |
| NEWS | 12 | OCT 17 | STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAPLUS documents for use in third-party analysis and visualization tools |
| NEWS | 13 | OCT 27 | Free KWIC format extended in full-text databases |
| NEWS | 14 | OCT 27 | DIOGENES content streamlined |
| NEWS | 15 | OCT 27 | EPFULL enhanced with additional content |
| NEWS EXPRESS | | | JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005 |
| NEWS HOURS | | | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | | | General Internet Information |
| NEWS LOGIN | | | Welcome Banner and News Items |
| NEWS PHONE | | | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | | | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:16:49 ON 29 OCT 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

10/530,101

FULL ESTIMATED COST

| ENTRY | SESSION |
|-------|---------|
| 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 11:16:58 ON 29 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 OCT 2005 HIGHEST RN 866318-76-5
DICTIONARY FILE UPDATES: 27 OCT 2005 HIGHEST RN 866318-76-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*



Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\105301012.str



chain nodes :
18
ring nodes :

10/530,101

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

5-13 14-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11 11-12 13-14
14-15

exact/norm bonds :

7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15 14-18

exact bonds :

5-13 8-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

G1:O,S,N,X,Ak,CN,NO2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N,X,Ak,CN,NO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 11:17:21 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 36 TO ITERATE

100.0% PROCESSED 36 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**


10/530,101

BATCH **COMPLETE**
PROJECTED ITERATIONS: 360 TO 1080
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> d scan

L2 1 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazolo[1,5-a]pyridine-2-methanol, 3-[2-(methylthio)-4-pyrimidinyl]-
α-phenyl- (9CI)
MF C19 H16 N4 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful
FULL SEARCH INITIATED 11:17:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 637 TO ITERATE

100.0% PROCESSED 637 ITERATIONS 32 ANSWERS
SEARCH TIME: 00.00.01

L3 32 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| | 161.33 | 161.54 |

FILE 'CAPLUS' ENTERED AT 11:17:43 ON 29 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Oct 2005 VOL 143 ISS 19
FILE LAST UPDATED: 28 Oct 2005 (20051028/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 3 L3

=> d 15 1-3 bib hitstr

L5 NOT FOUND

The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d 14 1-3 bib hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:333716 CAPLUS

DN 140:357367

TI Preparation of pyrazolopyridines for the prophylaxis or treatment of a
herpes viral infection

IN Gudmundsson, Kristjan S.; Johns, Brian A.

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|-----------------|----------|
| PI | WO 2004033454 | A1 | 20040422 | WO 2003-US30334 | 20030924 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | EP 1546148 | A1 | 20050629 | EP 2003-759540 | 20030924 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| PRAI | US 2002-415939P | P | 20021003 | | |
| | WO 2003-US30334 | W | 20030924 | | |
| OS | MARPAT 140:357367 | | | | |
| IT | 681261-91-6P , 2-Isobutyl-3-(2-(methylthio)pyrimidin-4-yl)pyrazolo[1,5-a]pyridine 681261-92-7P , 2-Isobutyl-3-(2-(methylsulfinyl)pyrimidin-4-yl)pyrazolo[1,5-a]pyridine 681261-93-8P , N-Cyclopentyl-4-(2-isobutylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine 681261-94-9P , N-Cyclopentyl-4-(2-isobutyl-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine 681261-95-0P , N-Cyclopentyl-4-(2-isobutyl-7-(methylsulfinyl)pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine 681261-97-2P , 2-(Diethoxymethyl)-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 681261-98-3P , 3-[2- | | | | |


(Methylthio)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine-2-carboxaldehyde
681261-99-4P 681262-00-0P 681262-03-3P,
 4-(2-Benzylpyrazolo[1,5-a]pyridin-3-yl)-N-cyclopentyl-2-pyrimidinamine
681262-04-4P, 4-(2-Benzyl-7-chloropyrazolo[1,5-a]pyridin-3-yl)-N-cyclopentyl-2-pyrimidinamine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrazolopyridines for the prophylaxis or treatment of a herpes viral infection)


RN 681261-91-6 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-(2-methylpropyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681261-92-7 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-(2-methylpropyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681261-93-8 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-methylpropyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 681261-94-9 CAPLUS


CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-methylpropyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



10/530,101


RN 681261-95-0 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-methylpropyl)-7-(methylsulfinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 681261-97-2 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-(diethoxymethyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681261-98-3 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-carboxaldehyde, 3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681261-99-4 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-methanol, 3-[2-(methylthio)-4-pyrimidinyl]- α -phenyl- (9CI) (CA INDEX NAME)




RN 681262-00-0 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-methanol, 3-[2-(cyclopentylamino)-4-pyrimidinyl]- α -phenyl- (9CI) (CA INDEX NAME)




RN 681262-03-3 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(phenylmethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 681262-04-4 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(phenylmethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



IT 681261-96-1P, N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-isobutylpyrazolo[1,5-a]pyridin-7-amine 681262-01-1P

681262-02-2P 681262-05-5P 681262-06-6P,

N-Cyclopentyl-4-[2-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 681262-07-7P, N-Cyclopentyl-4-[2-(methoxymethyl)-

7-(methylsulfanyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine

681262-08-8P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(methoxymethyl)pyrazolo[1,5-a]pyridin-7-amine 681262-09-9P

681262-10-2P, N-([3-[2-(Methylsulfanyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl)methyl)-2-propanamine 681262-11-3P,

N-Cyclopentyl-4-[2-[(isopropylamino)methyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 681262-12-4P, N-Cyclopentyl-3-[2-

(cyclopentylamino)-4-pyrimidinyl]-2-[(isopropylamino)methyl]pyrazolo[1,5-a]pyridin-7-amine 681262-13-5P, 4-[7-Chloro-2-[3-

(isopropylamino)propyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 681262-14-6P, N-Cyclopentyl-3-[2-

(cyclopentylamino)-4-pyrimidinyl]-2-[3-(isopropylamino)propyl]pyrazolo[1,5-a]pyridin-7-amine 681262-15-7P, 4-[7-Chloro-2-[(2-

methoxyethoxy)methyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 681262-16-8P, 3-[2-(Cyclopentylamino)-4-

pyrimidinyl]-2-[(2-methoxyethoxy)methyl]-N-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-7-amine 681262-17-9P, N-Cyclopentyl-3-[2-

(cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)methyl]pyrazolo[1,5-


alpyridin-7-amine **681262-18-0P**, N-Cyclopentyl-4-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine
681262-19-1P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-isopropylpyrazolo[1,5-a]pyridin-7-amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyridines for the prophylaxis or treatment of a herpes viral infection)


RN 681261-96-1 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 681262-01-1 CAPLUS

CN Methanone, [3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl- (9CI) (CA INDEX NAME)



RN 681262-02-2 CAPLUS


CN Methanone, [7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl- (9CI) (CA INDEX NAME)



RN 681262-05-5 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-

pyrimidinyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 681262-06-6 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 681262-07-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(methoxymethyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 681262-08-8 CAPLUS



CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)



10/530,101


RN 681262-09-9 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 681262-10-2 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-methanamine, N-(1-methylethyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681262-11-3 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-methanamine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 681262-12-4 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-methanamine, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 681262-13-5 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-propanamine, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 681262-14-6 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-propanamine, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 681262-15-7 CAPLUS


CN 2-Pyrimidinamine, 4-[7-chloro-2-[(2-methoxyethoxy)methyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



10/530,101


RN 681262-16-8 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 681262-17-9 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 681262-18-0 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 681262-19-1 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:658126 CAPLUS
DN 137:201324
TI Preparation of 4-(imidazo[1,2-a]pyrid-3-yl/pyrazolo[2,3-a]pyrid-3-yl)-2-arylamino pyrimidines for the treatment of GSK3-related disorders
IN Berg, Stefan; Bhat, Ratan; Hellberg, Sven
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2002066480 | A2 | 20020829 | WO 2002-SE270 | 20020218 |
| | WO 2002066480 | A3 | 20040401 | | |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2435177 | AA | 20020829 | CA 2002-2435177 | 20020218 |
| | BR 2002007096 | A | 20040120 | BR 2002-7096 | 20020218 |
| | EP 1423388 | A2 | 20040602 | EP 2002-712572 | 20020218 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2004522777 | T2 | 20040729 | JP 2002-565994 | 20020218 |
| | ZA 2003006175 | A | 20041108 | ZA 2003-6175 | 20030808 |
| | NO 2003003677 | A | 20031002 | NO 2003-3677 | 20030819 |
| | US 2004106574 | A1 | 20040603 | US 2003-468605 | 20030819 |
| PRAI | US 2001-269903P | P | 20010220 | | |
| | WO 2002-SE270 | W | 20020218 | | |

OS MARPAT 137:201324


IT **328061-44-5P 328061-67-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-(imidazo[1,2-a]pyrid-3-yl/pyrazolo[2,3-a]pyrid-3-yl)-2-arylamino pyrimidines for the treatment of GSK3-related disorders)

RN 328061-44-5 CAPLUS


CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



10/530,101

RN 328061-67-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2-methylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 328064-22-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-(imidazo[1,2-a]pyrid-3-yl/pyrazolo[2,3-a]pyrid-3-yl)-2-arylamino pyrimidines for the treatment of GSK3-related disorders)

RN 328064-22-8 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-methyl-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:152681 CAPLUS

DN 134:193444

TI Preparation of imidazo[1,2-a]pyridinylpyrimidines and pyrazolo[2,3-a]pyridinylpyrimidines as inhibitors of CDK2, CDK4, and CDK6 cell cycle kinases.

IN Thomas, Andrew Peter; Breault, Gloria Anne; Beattie, John Franklin; Jewsbury, Phillip John

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 81 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2001014375 | A1 | 20010301 | WO 2000-GB3139 | 20000815 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2376293 | AA | 20010301 | CA 2000-2376293 | 20000815 |
| | BR 2000013476 | A | 20020430 | BR 2000-13476 | 20000815 |
| | EP 1214318 | A1 | 20020619 | EP 2000-953319 | 20000815 |

EP 1214318 B1 20031008
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
 JP 2003507478 T2 20030225 JP 2001-518706 20000815
 AU 757639 B2 20030227 AU 2000-65833 20000815
 EE 200200080 A 20030616 EE 2002-80 20000815
 AT 251623 E 20031015 AT 2000-953319 20000815
 PT 1214318 T 20040227 PT 2000-953319 20000815
 ES 2208397 T3 20040616 ES 2000-953319 20000815
 NZ 516740 A 20040924 NZ 2000-516740 20000815
 RU 2248976 C2 20050327 RU 2002-107128 20000815
 ZA 2002000028 A 20030402 ZA 2002-28 20020102
 BG 106383 A 20020930 BG 2002-106383 20020204
 NO 2002000832 A 20020412 NO 2002-832 20020220
 US 6855719 B1 20050215 US 2002-69019 20020221
 HK 1045510 A1 20040319 HK 2002-107002 20020925
 PRAI GB 1999-19778 A 19990821
 WO 2000-GB3139 W 20000815
 OS MARPAT 134:193444
 IT **328061-44-5P 328061-67-2P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazo[1,2-a]pyridinylpyrimidines and pyrazolo[2,3-a]pyridinylpyrimidines as inhibitors of CDK2, CDK4, and CDK6 cell cycle kinases)
 RN 328061-44-5 CAPLUS
 CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 328061-67-2 CAPLUS
 CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2-methylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT **328064-22-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazo[1,2-a]pyridinylpyrimidines and pyrazolo[2,3-a]pyridinylpyrimidines as inhibitors of CDK2, CDK4, and CDK6 cell cycle kinases)
 RN 328064-22-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-methyl-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/530,101



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.62

172.16

FILE 'CAOLD' ENTERED AT 11:18:32 ON 29 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 13

L5

0 L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.43

172.59

STN INTERNATIONAL LOGOFF AT 11:18:39 ON 29 OCT 2005